Adjuvance Technologies

Empowering health.

Board of Directors

ADJUVANCE PARTICIPATES IN THE BIO CEO AND INVESTORS CONFERENCE
ADJUVANCE PRESENTS ITS 2021 POTENTIAL AND PLANS AT THE BIOTECH SHOWCASE
ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine